Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Intravenous Ravulizumab in Adults at High Risk of Delayed Graft Function After Kidney Transplantation
jRCT2051250092Phase 3Recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in delayed graft function (DGF) and end-stage kidney disease (ESKD) comparing Ravulizumab with Placebo (2 arms). Primary endpoint: Time to freedom from dialysis through 90 days post-transplant. Started Apr 2026; status: recruiting.
02
Drugs
ravulizumab
03
Conditions
delayed graft function (DGF)end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on jRCT2051250092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250092.